NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • A Guide to What We Do
    • Activities during COVID-19
    • Strategic Partnership Board
    • Steering Committee
    • Promoting Equality, Diversity and Inclusion in Research
    • Current Vacancies
    • Contact Us
    • Stay in Touch
  • Research
        • OUR 20 RESEARCH THEMES

        • Antimicrobial Resistance and Modernising Microbiology
        • Cardiovascular
        • Clinical Informatics and Big Data
        • Diabetes and Metabolism
        • Gastroenterology and Mucosal Immunity
        • Genomic Medicine
        • Haematology and Stem Cells
        • Imaging
        • Molecular Diagnostics
        • Multi-Modal Cancer Therapies
        • Multi-Morbidity and Long-Term Conditions
        • Musculoskeletal
        • Neurological Conditions
        • Obesity, Diet and Lifestyle
        • Partnerships for Health, Wealth and Innovation
        • Respiratory
        • Stroke and Vascular Dementia
        • Surgical Innovation and Evaluation
        • Technology and Digital Health
        • Vaccines for Emerging and Endemic Diseases
        • Oxford Biomedical Research Centre activities during COVID-19
  • Patient & Public Involvement
    • Getting involved with research
    • Researcher Guidance
    • Post an opportunity for patient and public involvement
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Preparatory Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • What Can We Do For Your Organisation?
    • Who Do We Work With?
    • IP and Licensing
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > Gastroenterology and Mucosal Immunity > Oxford collaborates with Janssen to map the cellular landscape of immune mediated disorders

Oxford collaborates with Janssen to map the cellular landscape of immune mediated disorders

16 February 2021 · Listed under Gastroenterology and Mucosal Immunity

The University of Oxford has entered into a strategic collaboration with Janssen Biotech to develop a cellular map of genes and proteins implicated across a range of immune-mediated inflammatory disorders and to characterise pharmacologically relevant therapeutic targets.

Photo by Louis Reed on Unsplash

Lead Oxford investigator for the project, Professor Holm Uhlig, said: “This exciting endeavour brings together a world-leading group of Janssen and Oxford scientists to form the Cartography collaboration.

“This project aims to create a detailed cellular map across multiple immune disorders which has the potential to advance the understanding of disease mechanisms, how to treat the right patients with the right medications, and the development of new therapies.”

The work of this industry/academic collaboration overlaps considerably with and complements the interdisciplinary research being carried out by scientists like Prof Uhlig in the NIHR Oxford BRC’s Gastroenterology and Mucosal Immunity Theme.

Immune mediated inflammatory disorders affect a large proportion of the population. Genetic association studies, functional studies, and clinical observations suggest that there is substantial overlap between immune mediated inflammatory disorders affecting different organ systems, but the cellular mechanisms are largely unknown.

This three-year data-driven study, will apply the latest molecular and cellular multiomics analysis platforms and computational methods to deliver insights for target selection and precision medicine for inflammatory disease indications of the intestine, the joint and the skin where existing options for therapeutic intervention are limited.

The collaboration will create four new postdoctoral positions at the University of Oxford.

Janssen Biotech Inc. is one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

← Paper urges use of genomics in care of monogenic IBD
Oxford academics named NIHR Senior Investigators →

News

  • Lymph nodes reveal more about mechanisms of autoimmunity 14 June 2022
  • Conference aims to forge collaborations to tackle dementia 9 June 2022
  • Lung function device wins top chemistry Prize 8 June 2022
See full news archive

News Categories

Month Archives

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Oxford BRC on Social Media

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

  • Sitemap
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2022 NIHR Oxford Biomedical Research Centre